Since Retatrutide is not FDA-approved and remains a research-only peptide , its full safety profile has not yet been established
Am J Physiol 261:H1053H1059 Hotta K, Kuwajima M, Ono A, Nakajima H, Horikawa Y, Miyagawa J, Namba M, Hanafusa T, Horiuchi M, Nikaido H, Hayakawa J, Saheki T, Kono N, Noguchi T, Matsuzawa Y (1996) Disordered expression of glycolytic and gluconeogenic liver enzymes of juvenile visceral steatosis mice with systemic carnitine deficiency
In some cases, depending on the formulation and provider, there may be oral versions such as tablets or drops
Experimental receptor assays demonstrate that Retatrutide functions as an agonist at all three receptors, although the peptide exhibits differing potency levels across the receptor set